

# EXAMINER SEARCH NOTES

FILE 'CAPLUS, MEDLINE' ENTERED AT 15:31:38 ON 21 JUN 2005

L4	143 S L3
L5	110553 S OBESITY
L6	4 S L4 AND L5
L7	136 S HALOFENATE
L8	3 S L7 AND L5
L9	0 S L8 NOT L6

=>

FILE 'REGISTRY' ENTERED AT 15:28:28 ON 21 JUN 2005

L1 0 S ?"ACETAMINIDOETHYL-4-CHLOROPHENYL- (3-TRIFLUOROMETHYLPHENOXY)  
L2 0 S ?"ACETATE, ACETAMIDOETHYL-4-CHLOROPHENYL- (3-TRIFLUOROMETHYLPH  
L3 3 S ?"ACETAMIDOETHYL-4-CHLOROPHENYL- (3-TRIFLUOROMETHYLPHENOXY"?/C

FILE 'CAPLUS, MEDLINE' ENTERED AT 15:31:38 ON 21 JUN 2005

L4 143 S L3  
L5 110553 S OBESITY  
L6 4 S L4 AND L5

=> d l6 1-4 bib abs

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:930984 CAPLUS  
DN 140:4856  
TI Preparation and use of (-)-(3-trihalomethylphenoxy)(4-halophenyl)acetates  
for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and  
hyperuricemia.  
IN Luskey, Kenneth L.; Luo, Jian  
PA Metabolex, Inc., USA; Diatex, Inc.  
SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 724,788.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003220399	A1	20031127	US 2003-382186	20030304
	US 6262118	B1	20010717	US 1999-325997	19990604
	US 6613802	B1	20030902	US 2000-585907	20000602
	US 6646004	B1	20031111	US 2000-703487	20001031
	US 6624194	B1	20030923	US 2000-724788	20001128
	US 2005075396	A1	20050407	US 2003-660112	20030910
PRAI	US 1999-325997	A1	19990604		
	US 2000-585907	A2	20000602		
	US 2000-703487	A2	20001031		
	US 2000-724788	A2	20001128		

OS MARPAT 140:4856  
AB A method of treating type II diabetes comprises administration of the  
(-)-stereoisomer of 4-XC6H4CH(CO2R)OC6H4CX3-3 (R = OH, aralkoxy,  
dialkylaminoalkoxy, alkanamidoalkoxy, benzamidoalkoxy, ureidoalkoxy,  
alkylureidoalkoxy, carbamoylalkoxy, halophenoxyalkoxy, carbamoylphenoxy,  
carbonylalkylamino, dialkylaminoalkylamino, haloalkylamino,  
hydroxyalkylamino, alkanolyloxyalkylamino, ureido, alkoxycarbonylamino; X  
= halo). Thus, a mixture of DMF, pyridine, and N-acetylethanolamine at  
0-5° was treated with a solution of crude (-)-4-chlorophenyl(3-  
trifluoromethylphenoxy)acetyl chloride in ether over 40 min. at  
<13°; the mixture was stirred at ambient temperature for 16 h to give 73%  
(-)-2-acetamidoethyl 4-chlorophenyl(3-trifluoromethylphenoxy)acetate  
[(-)-halofenate]. (-)-Halofenate at 50 mg/kg orally in rats significantly  
reduced plasma glucose, while (+)-halofenate did not.


L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:428842 CAPLUS  
DN 137:15795  
TI Use of (-)-(3-halomethylphenoxy)-(4-halophenyl)acetic acid derivatives for  
treatment of insulin resistance, type 2 diabetes, hyperlipidemia, and  
hyperuricemia, and preparation thereof  
IN Lusky, Kenneth L.; Luo, Jian; Zhao, Zuchun  
PA Metabolex, Inc., USA  
SO PCT Int. Appl., 133 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044113	A2	20020606	WO 2001-US44603	20011128

WO 2002044113 C2 20030501  
 WO 2002044113 A3 20020912  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,  
 PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 US 6624194 B1 20030923 US 2000-724788 20001128  
 CA 2430199 AA 20020606 CA 2001-2430199 20011128  
 AU 2002039371 A5 20020611 AU 2002-39371 20011128  
 EP 1343493 A2 20030917 EP 2001-987124 20011128  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 US 2004039053 A1 20040226 US 2003-432742 20030527  
 PRAI US 2000-724788 A 20001128  
 US 1999-325997 A2 19990604  
 US 2000-585907 A2 20000602  
 WO 2001-US44603 W 20011128  
 OS MARPAT 137:15795  
 AB The invention provides the use of (-)-(3-halomethylphenoxy)  
 (4-halophenyl)acetic acid derivs. and compns. in the treatment of insulin  
 resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. It further  
 provides (-)-(3-halomethylphenoxy)-(4-halophenyl) acetic acid derivs. that  
 are useful for the treatment of insulin resistance, Type 2 diabetes,  
 hyperlipidemia and hyperuricemia.  
 L6 ANSWER 3 OF 4 MEDLINE on STN  
 AN 78159741 MEDLINE  
 DN PubMed ID: 347582  
 TI Hyperlipidemia in primary gout.  
 AU Yu T F; Dorph D J; Smith H  
 SO Seminars in arthritis and rheumatism, (1978 May) 7 (4) 233-44. Ref: 71  
 Journal code: 1306053. ISSN: 0049-0172.  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 LA English  
 FS Priority Journals  
 EM 197806  
 ED Entered STN: 19900314  
 Last Updated on STN: 19900314  
 Entered Medline: 19780628  
 L6 ANSWER 4 OF 4 MEDLINE on STN  
 AN 77244909 MEDLINE  
 DN PubMed ID: 330079  
 TI Effects of halofenate and probenecid on serum lipids and uric acid in  
 hyperlipidemic, hyperuricemic adults.  
 AU Bassett D R; Mikkelsen W M; Buckingham R B; Block W D; Sidiq M; Shakibai  
 A; DiGaetano R; Liou L L  
 SO Clinical pharmacology and therapeutics, (1977 Sep) 22 (3) 340-51.  
 Journal code: 0372741. ISSN: 0009-9236.  
 CY United States  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Abridged Index Medicus Journals; Priority Journals  
 EM 197710  
 ED Entered STN: 19900314  
 Last Updated on STN: 19900314  
 Entered Medline: 19771028

L10 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 23953-39-1 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Benzeneacetic acid, 4-chloro- $\alpha$ -[3-(trifluoromethyl)phenoxy]-, (-)-(9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Acetic acid, (p-chlorophenyl)[( $\alpha,\alpha,\alpha$ -trifluoro-m-tolyl)oxy]-, (-)-(8CI)  
 OTHER NAMES:  
 CN (-)-(4-Chlorophenyl)(3-trifluoromethylphenoxy)acetic acid  
 FS STEREOSEARCH  
 MF C15 H10 Cl F3 O3  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL  
 (\*File contains numerically searchable property data)


Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L10 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 4687-08-5 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Benzeneacetic acid, 4-chloro- $\alpha$ -[3-(trifluoromethyl)phenoxy]- (9CI)  
 (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Acetic acid, (p-chlorophenyl)[( $\alpha,\alpha,\alpha$ -trifluoro-m-tolyl)oxy]- (7CI, 8CI)  
 OTHER NAMES:  
 CN  $\alpha$ -(p-Chlorophenyl)- $\alpha$ -(m-trifluoromethylphenoxy)acetic acid  
 CN 2-(p-Chlorophenyl)-2-(m-trifluoromethylphenoxy)acetate  
 CN 4-Chlorophenyl(3-trifluoromethylphenoxy)acetic acid  
 CN MK 185 FA  
 FS 3D CONCORD  
 MF C15 H10 Cl F3 O3  
 CI COM  
 LC STN Files: BEILSTEIN\*, CA, CAOLD, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATFULL  
 (\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

20 REFERENCES IN FILE CA (1907 TO DATE)

FILE 'REGISTRY' ENTERED AT 15:28:28 ON 21 JUN 2005  
L1 0 S ?"ACETAMINIDOETHYL-4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)  
L2 0 S ?"ACETATE, ACETAMIDOETHYL-4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPH  
L3 3 S ?"ACETAMIDOETHYL-4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY"?/C

FILE 'CAPLUS, MEDLINE' ENTERED AT 15:31:38 ON 21 JUN 2005  
L4 143 S L3  
L5 110553 S OBESITY  
L6 4 S L4 AND L5  
L7 136 S HALOFENATE  
L8 3 S L7 AND L5  
L9 0 S L8 NOT L6

FILE 'REGISTRY' ENTERED AT 15:35:08 ON 21 JUN 2005  
L10 8 S ?"CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY"?/CNS

FILE 'CAPLUS, MEDLINE' ENTERED AT 15:37:36 ON 21 JUN 2005  
L11 9 S 23953-39-1/RN  
L12 20 S 4687-08-5/RN  
L13 22 S L11 OR L12  
L14 0 S ?"CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY"?/CNS  
L15 0 S ?"CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY"?

=> s l13 and l5  
L16 2 L13 AND L5

=> d 1-2 bib abs

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2003:930984 CAPLUS  
DN 140:4856  
TI Preparation and use of (-)-(3-trihalomethylphenoxy)(4-halophenyl)acetates  
for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and  
hyperuricemia.  
IN Luskey, Kenneth L.; Luo, Jian  
PA Metabolex, Inc., USA; Diatex, Inc.  
SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 724,788.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003220399	A1	20031127	US 2003-382186	20030304
	US 6262118	B1	20010717	US 1999-325997	19990604
	US 6613802	B1	20030902	US 2000-585907	20000602
	US 6646004	B1	20031111	US 2000-703487	20001031
	US 6624194	B1	20030923	US 2000-724788	20001128
	US 2005075396	A1	20050407	US 2003-660112	20030910
PRAI	US 1999-325997	A1	19990604		
	US 2000-585907	A2	20000602		
	US 2000-703487	A2	20001031		
	US 2000-724788	A2	20001128		
OS	MARPAT 140:4856				

AB A method of treating type II diabetes comprises administration of the  
(-)-stereoisomer of 4-XC6H4CH(CO2R)OC6H4CX3-3 (R = OH, aralkoxy,  
dialkylaminoalkoxy, alkanamidoalkoxy, benzamidoalkoxy, ureidoalkoxy,  
alkylureidoalkoxy, carbamoylalkoxy, halophenoxyalkoxy, carbamoylphenoxy,  
carbonylalkylamino, dialkylaminoalkylamino, haloalkylamino,  
hydroxyalkylamino, alkanolyloxyalkylamino, ureido, alkoxycarbonylamino; X  
= halo). Thus, a mixture of DMF, pyridine, and N-acetyethanolamine at  
0-5° was treated with a solution of crude (-)-4-chlorophenyl(3-  
trifluoromethylphenoxy)acetyl chloride in ether over 40 min. at  
<13°; the mixture was stirred at ambient temperature for 16 h to give 73%  
(-)-2-acetamidoethyl 4-chlorophenyl(3-trifluoromethylphenoxy)acetate  
[(-)-halofenate]. (-)-Halofenate at 50 mg/kg orally in rats significantly  
reduced plasma glucose, while (+)-halofenate did not.

AN 2002:428842 CAPLUS

DN 137:15795

TI Use of (-)-(3-halomethylphenoxy)-(4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia, and hyperuricemia, and preparation thereof

IN Lusky, Kenneth L.; Luo, Jian; Zhao, Zuchun

PA Metabolex, Inc., USA

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044113	A2	20020606	WO 2001-US44603	20011128
	WO 2002044113	C2	20030501		
	WO 2002044113	A3	20020912		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 6624194	B1	20030923	US 2000-724788	20001128
	CA 2430199	AA	20020606	CA 2001-2430199	20011128
	AU 2002039371	A5	20020611	AU 2002-39371	20011128
	EP 1343493	A2	20030917	EP 2001-987124	20011128
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	US 2004039053	A1	20040226	US 2003-432742	20030527
PRAI	US 2000-724788	A	20001128		
	US 1999-325997	A2	19990604		
	US 2000-585907	A2	20000602		
	WO 2001-US44603	W	20011128		

OS MARPAT 137:15795

AB The invention provides the use of (-)-(3-halomethylphenoxy)(4-halophenyl)acetic acid derivs. and compns. in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. It further provides (-)-(3-halomethylphenoxy)-(4-halophenyl) acetic acid derivs. that are useful for the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

=&gt;